Welcome to our dedicated page for Vaxcyte news (Ticker: PCVX), a resource for investors and traders seeking the latest updates and insights on Vaxcyte stock.
Vaxcyte, Inc. (Nasdaq: PCVX) is a pioneering biopharmaceutical company based in San Carlos, California, dedicated to developing high-fidelity vaccines to protect against serious bacterial infections. Vaxcyte aims to improve global health through innovative vaccines designed to prevent diseases that conventional options fail to address effectively.
The company's flagship product, VAX-24, is a 24-valent pneumococcal conjugate vaccine (PCV) designed to provide broad-spectrum protection against invasive pneumococcal disease (IPD). VAX-24 is engineered to cover more strains than the current leading vaccines, addressing a significant unmet need in both adult and pediatric populations. Vaxcyte's advanced cell-free protein synthesis platform, XpressCF™, is pivotal in developing these complex conjugate vaccines, allowing for efficient production and enhanced immunogenicity.
Vaxcyte's pipeline includes VAX-31, a next-generation 31-valent PCV, currently in Phase 1/2 clinical trials. VAX-31 aims to achieve the broadest coverage of any PCV to date, targeting 95% of IPD strains circulating in the U.S. adult population. Additionally, the company is developing other promising vaccine candidates such as VAX-A1 for Group A Strep infections, VAX-PG for periodontal disease, and VAX-GI for Shigella prevention.
Recent milestones include the successful completion of enrollment in the VAX-31 Phase 1/2 trial and the VAX-24 infant Phase 2 study. The FDA granted Breakthrough Therapy designation to VAX-24, reflecting its potential to offer substantial improvements over existing treatments. Vaxcyte is on track to advance VAX-24 into Phase 3 trials, with topline data anticipated by 2025.
Financially, Vaxcyte is robust, supported by $1.4 billion in recent follow-on equity financings to advance its vaccine candidates and expand its manufacturing capabilities.
For more information, visit www.vaxcyte.com.
Vaxcyte, Inc. (Nasdaq: PCVX) reported its financial results for Q1 2022, highlighting a cash position of $352.3 million, which includes net proceeds of approximately $107.6 million from a recent public offering. The company is advancing its Phase 1/2 clinical study for VAX-24, a 24-valent pneumococcal conjugate vaccine, with topline results expected by the end of 2022. Additionally, a separate Phase 2 study for adults aged 65 and older is anticipated to begin mid-2022. Total operating expenses for the quarter were $39.2 million, resulting in a net loss of $39.0 million.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in notable investor conferences, including the BofA Securities 2022 Healthcare Conference from May 10-13 in Las Vegas and the UBS Global Healthcare Conference from May 23-25 in New York. At the BofA conference, a fireside chat is scheduled for May 10 at 5:40 p.m. ET, with one-on-one meetings on May 10 and 11. Webcast access is available on the company’s website. Vaxcyte is focused on developing high-fidelity vaccines to combat bacterial diseases, including its lead candidate VAX-24.
Vaxcyte, Inc. (Nasdaq: PCVX) announced its participation in the 21st Annual Needham Virtual Healthcare Conference on April 12, 2022, at 12:45 p.m. ET. The event will feature a fireside chat with company management, accessible via a live webcast on Vaxcyte's website. The presentation will be available for replay for 30 days after the conference. Vaxcyte focuses on developing innovative vaccines for bacterial diseases, including its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease and pneumonia.
Vaxcyte announced the dosing of the first participants in the Phase 2 portion of its Phase 1/2 clinical trial for VAX-24, a 24-valent pneumococcal conjugate vaccine. The independent Data Monitoring Committee recommended proceeding after reviewing Phase 1 safety data. Vaxcyte aims to deliver broader protection against invasive pneumococcal disease and pneumonia. Topline results from both trial phases are expected by the end of 2022, highlighting the candidate's potential to improve standard vaccination practices.
Vaxcyte, Inc. (PCVX) announced the initiation of a Phase 1/2 clinical study for its 24-valent pneumococcal conjugate vaccine, VAX-24, aimed at preventing invasive pneumococcal disease in adults. The study's topline safety and immunogenicity results are expected by the end of 2022. The company reported a cash position of $273.1 million as of December 31, 2021, excluding $107.6 million from a recent public offering. Vaxcyte also highlighted increased R&D costs and a net loss of $100.1 million for 2021, signaling ongoing investment in its vaccine pipeline.
Vaxcyte (PCVX) announced the initiation of a Phase 1/2 clinical study for VAX-24, a 24-valent pneumococcal conjugate vaccine. This proof-of-concept study will assess the safety, tolerability, and immunogenicity of VAX-24 in adults, with topline results expected by the end of 2022. The study aims to prevent invasive pneumococcal disease and pneumonia, which significantly affect public health. The vaccine targets emerging serotypes not included in existing vaccines, addressing the significant morbidity and mortality associated with pneumococcal diseases.
Vaxcyte, Inc. (PCVX) will report its fourth quarter and full year 2021 financial results on February 28, 2022, after market close. The management will host a conference call at 4:30 p.m. ET to discuss these results and provide a business update. Vaxcyte is focused on developing innovative vaccines, with its lead candidate being VAX-24, a 24-valent pneumococcal conjugate vaccine aimed at preventing invasive pneumococcal disease. The company utilizes advanced synthetic techniques, including the XpressCF™ platform, to enhance vaccine efficacy and production.
Vaxcyte (Nasdaq: PCVX) announced that management will present at the 11th Annual SVB Leerink Global Healthcare Conference on February 18, 2022. The presentation is set for 2:20 p.m. ET / 11:20 a.m. PT. A live webcast will be available on the company’s website, with a replay accessible for 30 days post-conference. Vaxcyte focuses on engineering high-fidelity vaccines to combat bacterial diseases, with its lead candidate, VAX-24, aimed at preventing invasive pneumococcal disease.
Vaxcyte, Inc. (Nasdaq: PCVX) has announced a public offering of 2,500,000 shares of common stock and pre-funded warrants, priced at $20.00 and $19.999 per share, respectively. The offering is expected to generate approximately $100 million in gross proceeds, excluding the exercise of warrants. The offering is anticipated to close on January 18, 2022, subject to customary conditions. Vaxcyte has also granted underwriters a 30-day option for an additional 750,000 shares.
Vaxcyte, Inc. (Nasdaq: PCVX) announced a public offering of common stock and pre-funded warrants, with underwriters having a 30-day option to purchase an additional 15% of shares. The offering's terms are subject to market conditions and lack definitive timelines. Leading the offering are BofA Securities, Jefferies, and Evercore ISI. A shelf registration statement has been effective since July 2, 2021. The company's focus is on developing advanced vaccines, including its lead candidate, VAX-24, targeting invasive pneumococcal disease.
FAQ
What is the current stock price of Vaxcyte (PCVX)?
What is the market cap of Vaxcyte (PCVX)?
What is Vaxcyte, Inc.'s primary focus?
What are the key products in Vaxcyte's pipeline?
What makes VAX-24 different from existing vaccines?
What is the XpressCF™ platform?
What recent milestones has Vaxcyte achieved?
When is Vaxcyte expected to release data from its VAX-24 Phase 3 trials?
What financial support does Vaxcyte have for its projects?
Where can I find more information about Vaxcyte?
What is VAX-31 and its significance?
What other vaccine candidates is Vaxcyte developing?
